Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PBGENE-HBV

Gene editing · Gene editing: Hepatitis B virus cccDNA · developed by Precision BioSciences

Phase 1 Most advanced trial

DTIL Developer

1 Registered trials

What is PBGENE-HBV?

PBGENE-HBV is an in vivo gene editing agent built on the ARCUS platform, intended to edit hepatitis B virus DNA inside hepatocytes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene editing
Targets: Hepatitis B virus cccDNA
Mechanism: Gene editing: Hepatitis B virus cccDNA
Pathways: cccDNA elimination, inactivation of integrated HBV DNA in hepatocytes
Therapy area: Gastroenterology, Infectious disease
Developer: Precision BioSciences, Inc. (DTIL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06680232	Phase 1	HEPATITIS B CHRONIC	Recruiting	DTIL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HEPATITIS B CHRONIC

More from Precision BioSciences

PBGENE-DMD Phase 1/2

Sources

ClinicalTrials.gov NCT06680232

Updated Oct 11, 2026. Something wrong or missing? Report it on the DTIL page.

Follow DTIL, the company behind PBGENE-HBV

See DTIL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DTIL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z